BullScope
  • Home
  • Market News
  • Bargains & Bubbles
  • Expectations Audits
  • Research Notes
  • Said vs. Filed
  • The Economy
  • Evidence Sheets
  • Research Terminal
No Result
View All Result
SUBSCRIBE
BullScope
  • Home
  • Market News
  • Bargains & Bubbles
  • Expectations Audits
  • Research Notes
  • Said vs. Filed
  • The Economy
  • Evidence Sheets
  • Research Terminal
No Result
View All Result
BullScope
No Result
View All Result
Home Expectations Audits

Alphabet’s Margins Are the Best They’ve Ever Been. The Stock Assumes They Stay That Way Forever.

Moe Alsumidaie by Moe Alsumidaie
October 16, 2026
in Expectations Audits
0
74
SHARES
1.2k
VIEWS
Share on XShare on LinkedInShare on Facebook

A 34% operating margin and a share price sitting meaningfully below its peak: those two facts should not coexist in a simple story. Either the margin is under pressure from the capital cycle, or the current price reflects assumptions about durability that the filed numbers do not yet confirm, and the evidence for each side is what this piece examines.

In one breath

Alphabet’s Q2 2026 filing shows operating margins at 34%, a level the company has never sustained across a full year. Our data puts the stock’s price-to-sales ratio at the 92nd percentile of its own decade, meaning the market is paying a historically high premium per dollar of revenue. The open question is whether a capital expenditure program of this scale will compress those margins, and whether the current valuation already prices in that risk or does not, or whether Cloud’s acceleration makes the spending look cheap in hindsight.

The margin the filing shows

Alphabet spent most of the 2010s as a single-product company wearing a conglomerate’s name. The 2015 restructuring into a holding company was meant to give investors a cleaner view of the core advertising engine and the moonshots burning cash around it. For years, that transparency mostly confirmed what everyone suspected: Search was extraordinary, and everything else was expensive.

Then the numbers started moving. The 10-K filed February 5, 2026 shows full-year 2025 net income of $132 billion on revenue of $403 billion, a net margin of roughly a third. That is not a rounding error above the company’s own history: the business earned dramatically more per dollar of sales in 2025 than it did five years earlier, and it did so while revenue itself nearly doubled.

BullScope TerminalYou just read Alphabet’s filed numbers.Every claim above traces to a filing. Run any of 500+ companies through the same math-vs-mood engine. Free tier available.Open the Terminal →

The Q2 2026 operating margin of 34% extends that trend into the current year. For a business of this scale, that figure means something concrete: for every dollar a customer or advertiser sends Alphabet, thirty-four cents survive after paying every employee, every server lease, and every office light bill. A typical large manufacturer keeps about eight cents. The gap is what makes software businesses so interesting to study, and so dangerous to overpay for.

The margin the price assumes

Here is where the math and the mood diverge. “The math” is what the filed numbers justify on their own terms; “the mood” is what the market is currently willing to pay on top of that. Right now, the mood is generous.

Our data puts Alphabet’s price-to-sales ratio at the 92nd percentile of the company’s own history. A price-to-sales ratio is simply how many dollars the market pays per dollar of annual revenue, the way a buyer might pay ten times a shop’s annual sales to acquire it. Paying at the 92nd percentile of your own history means the market is betting that the next chapter is better than roughly nine of the last ten. The price-to-earnings multiple tells a similar story: elevated relative to the company’s own decade median, though not dramatically so on its own.

IF margins compress materially from current levels, the arithmetic of a 92nd-percentile price-to-sales ratio would require either a significant re-rating of the multiple or an acceleration in revenue growth to remain internally consistent, two scenarios with different implications that the filing does not yet resolve. And compression risk is exactly what the capital expenditure guidance is advertising.

The bill arriving in 2026

The Q2 2026 earnings call on July 22 carried a number that stopped several analysts mid-sentence: Alphabet raised its full-year capital expenditure guidance to roughly $200 billion. Capital expenditure is the money a company spends on physical assets, servers, cables, buildings, the infrastructure that future revenue runs on. Think of it as the renovation bill a restaurant pays before it can seat more diners.

BullScope TerminalAlphabet was the article. The engine is the product.Same yardsticks, any ticker: filed financials in, math-vs-mood out. Nothing here is advice; it is the evidence, organized.Run another company →

To feel the scale: the 2025 10-K shows Alphabet spent $91 billion on capital expenditures last year. The new guidance is more than twice that, in a single year. The consequence showed up immediately: free cash flow for Q2 turned negative, meaning the spending ran ahead of the earning, at least for now (Motley Fool, October 2026). Free cash flow is the money left after all spending, the cash a business can actually return to shareholders or reinvest freely. Negative free cash flow at a company generating enormous operating income in a single quarter is not a crisis, but it is a signal worth watching.

Management’s argument, made explicitly on the Q2 call, is that the constraint is capacity, not customers. Google Cloud’s revenue grew more than 80% year-over-year in Q2, and the backlog of signed but undelivered contracts reached $514 billion, with more than half expected to convert within two years. That backlog is larger than the entire company’s annual revenue. If the conversion rate holds, the spending looks prescient. If it slips, the margin story changes fast.

Where Cloud changes the arithmetic

Google Cloud reached a 35.6% operating margin in Q2 2026. That matters because Cloud was losing money as recently as a few years ago. A business segment that flips from loss to a margin matching Search in roughly three years does not behave like a mature advertising market; it behaves like a business still finding its ceiling.

As reported by Admiral Markets in an October 14, 2026 earnings preview (note: this characterisation derives from a secondary source rather than a primary Deepwater publication), Gene Munster of Deepwater Asset Management was cited as arguing that Meta’s new Muse personal AI agent poses a more serious threat to Google’s search advertising revenue than ChatGPT has, because Muse’s transactional design could route commercial queries around Google entirely. Search advertising generated tens of billions in Q2 2026 alone. If even a modest fraction of that traffic migrates, Cloud’s margin expansion would need to accelerate further just to keep the total margin flat.

That is the real tension inside the filing: two businesses moving in opposite directions at the same time, inside one stock price.

BullScope TerminalWant the full evidence sheet behind pieces like this?The terminal runs the complete workup: Alphabet and 500+ other names, on the same official data.See the evidence engine →

Reading the numbers

  • 34% operating margin, Q2 2026 (10-Q, June 2026): what it is, the share of each revenue dollar surviving after all operating costs. What it means here: this is the highest sustained margin in Alphabet’s history, up from 21% in 2022. In everyday terms, a corner store keeping 34 cents of every dollar after rent, wages, and stock would be considered extraordinary; most keep five to eight cents.
  • P/S ratio 10.7, at the 92nd percentile of the decade (our data): what it is, the price paid per dollar of annual revenue. What it means here: the market is paying more per dollar of Alphabet’s sales than it has in roughly nine of the last ten years. A household analogy: imagine paying $10.70 for a jar of jam that has historically sold for $6.70, because the jam has been unusually good lately and the buyer expects it to stay that way. Analyst consensus price targets as of October 2026 are also tracked by external sources (Beinsure), though BullScope’s percentile figure derives from our own historical data series.
  • $195 billion to $205 billion capex guidance, full-year 2026 (raised July 22, 2026): what it is, the planned spend on servers, data centers, and networking. What it means here: this is more than twice the $91 billion spent in all of 2025. A household earning $100,000 a year and planning to spend $50,000 on a home extension would feel this ratio; the extension may raise the home’s value, but the bills arrive before the appraisal does.
  • $514 billion Cloud backlog (10-Q, June 2026): what it is, signed contracts not yet converted to revenue. What it means here: more than a full year of Alphabet’s total 2025 revenue is already committed by Cloud customers. If conversion holds, the capex spending is building for a known order book, not a speculative one.

For the standing yardsticks on Alphabet: the price tag, the filed record, and the four gauges, refreshed with each edition, see the BullScope Evidence Sheet: Alphabet.

Sources

  • Alphabet 10-Q, quarter ended June 30, 2026 (SEC EDGAR)
  • Alphabet 10-K, fiscal year ended December 31, 2025 (SEC EDGAR)
  • Alphabet Q2 2026 Earnings Call (abc.xyz investor relations)
  • Alphabet Q2 2026 Earnings Call transcript (Betafinch)
  • Alphabet raises 2026 AI infrastructure spending target to $205 billion (Konsulteer)
  • Alphabet stock Q3 2026 earnings preview, citing Gene Munster as reported by Admiral Markets (secondary source)
  • Alphabet stock price forecast, analyst consensus October 2026 (Beinsure)
  • Alphabet negative free cash flow: why it matters (Motley Fool, October 2026)

Disclosure: BullScope holds no position in any security mentioned in this article. This article is impersonal financial analysis published for informational purposes only and does not constitute individualised investment advice or a recommendation to buy or sell any security. BullScope is a publisher of financial research and is not registered as an investment adviser; this content is provided solely for analytical and educational purposes and is excluded from the definition of investment advice under the Investment Advisers Act of 1940.

BullScope publishes impersonal research for a general audience. Nothing here is personalized investment advice, and nothing here is a recommendation to buy or sell any security. As of publication, neither BullScope nor its operator holds a position in any security, covered or otherwise; we do not trade at all, and we accept no compensation from any company we cover. When a conflict of interest exists, we do not publish: companies that compensate our operator in any capacity, or about which our operator could hold nonpublic information, are barred from coverage automatically, as described in the conflicts policy in our methodology. Figures come from company filings and public data through our published methodology; forecasts are conditional scenarios, not predictions and not promises. Markets carry risk, including loss of principal. Consider your own situation, or consult a licensed adviser, before acting on anything you read.
BullScope TerminalYou just read Alphabet’s filed numbers.Every claim above traces to a filing. Run any of 500+ companies through the same math-vs-mood engine. Free tier available.Open the Terminal →
Moe Alsumidaie

Moe Alsumidaie

Moe Alsumidaie, MBA, MSF, is founder and Chief Editor of Vanguard Publications, which publishes Clinical Trial Vanguard, Pharma Vanguard and BullScope, and Head of Research at CliniBiz. He has two decades in clinical trial operations and data science, with earlier roles at Genentech, Abbott Vascular and Stanford University Medical Center, and is a guest lecturer in clinical trial sciences at Rutgers University.

Recommended For You

Vertex Pharmaceuticals: Three Things the Street Is Saying, and What the Filings Actually Show

by Moe Alsumidaie
October 21, 2026
0

Vertex spent most of the last decade as a one-disease company that happened to be extraordinarily good at that disease. Cystic fibrosis is rare, the science is brutal,...

Read moreDetails

Merck’s Split Screen: Margins at a Decade High, a Stock Priced for Catastrophe

by Moe Alsumidaie
October 14, 2026
0

Two numbers sit side by side and refuse to make sense together. The 10-K filed in February 2026 shows Merck & Co, the US company that trades as...

Read moreDetails

Mirum Pharmaceuticals: A Pipeline on Fire, a Price That Went Cold

by Moe Alsumidaie
October 12, 2026
0

Three Phase 3 trials hit their primary endpoints in the span of two weeks. The stock is sitting roughly a third below its 52-week high. Those two facts...

Read moreDetails

Costco at $948: The Filed Numbers vs. What the Price Tag Demands

by Moe Alsumidaie
October 9, 2026
0

A stock sitting well below its 52-week high while posting the best operating margin in at least seven years. Those two facts should not coexist, and the gap...

Read moreDetails

Opko Health: A $1.46 Stock Priced Like a Winner, Filing Like a Turnaround in Progress

by Moe Alsumidaie
October 7, 2026
0

Before anything else The filed numbers show a company whose revenue has fallen roughly two-thirds from its 2020 peak, is burning through more cash than it earns, and...

Read moreDetails
Next Post

The $14 Acquisition Price and the Arbitrage Gap the Market Is Pricing

Please login to join discussion
BullScope
The Research Terminal
Run any stock through the BullScope evidence engine. Filings in, evidence out. Every number explains itself.
Open the Terminal
A BullScope product

Related News

Abbott’s Split Personality: Revenue Climbs 14%, the Stock Falls Anyway

October 22, 2026

Walmart’s operating income surges 28.8% as tariff refunds and eCommerce gains offset pricing pressure

August 24, 2026

Boeing renews 364-day credit line as operating margin stays thin at 4.8%

September 1, 2026
BullScope

BullScope is an evidence-first investment research publication. Every note starts in the filings: what companies actually report, what the market assumes, and where the two disagree. We read the numbers so you can read the story. Not investment advice.

Prefer BullScope.ai on Google

© 2026 BullScope. Evidence-first investment research. Not investment advice.  ·  Methodology  ·  Privacy Policy  ·  Terms of Use  ·  Disclaimer

No Result
View All Result
  • Home
  • Market News
  • Bargains & Bubbles
  • Expectations Audits
  • Research Notes
  • Said vs. Filed
  • The Economy
  • Evidence Sheets
  • Research Terminal

© 2026 BullScope. Evidence-first investment research. Not investment advice.  ·  Methodology  ·  Privacy Policy  ·  Terms of Use  ·  Disclaimer

Not enough quota to unlock this post
Unlock left : 0
Are you sure want to cancel subscription?
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.